Navigation Links
EntreMed Reports Receipt of Third Quarter Royalty Payment
Date:12/11/2009

ROCKVILLE, Md., Dec. 11 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD), today announced the receipt of $1.7 million in royalty revenue from sales of Thalomid® during the third quarter compared to estimated royalty revenue of $3.3 million. In addition, the Company anticipates a decrease in fourth quarter and projected revenue for fiscal 2009. The difference in estimated and actual revenues for the third quarter will be reflected in the fourth quarter financial results.

(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO )

EntreMed also plans to explore the sale of its rights to future royalties from sales of Thalomid® and has instituted additional expense reductions in non-clinical areas. EntreMed will continue ongoing activities in preparation for initiating a Phase II trial in ovarian cancer patients in the second quarter of 2010.

Thalomid® is a registered trademark of Celgene Corporation.

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company committed to developing primarily ENMD-2076, a selective angiogenic kinase inhibitor, for the treatment of cancer. ENMD-2076 is currently in Phase 1 studies in advanced cancers, multiple myeloma, and leukemia. The Company's other therapeutic candidates include MKC-1, an oral cell-cycle regulator with activity against the mTOR pathway currently in multiple Phase 2 clinical trials for cancer, and ENMD-1198, a novel antimitotic agent currently in Phase 1 studies in advanced cancers. The Company also has an approved IND application for Panzem® in rheumatoid arthritis. Additional information about EntreMed is available on the Company's web site at '/>"/>

SOURCE EntreMed, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. EntreMed to Present at ThinkEquity Partners 5th Annual Growth Conference
2. EntreMed Appoints Senior Vice President of Research and Development
3. EntreMed Announces FDA Acceptance of IND Application for Aurora Kinase/Angiogenesis Inhibitor, ENMD-2076
4. EntreMed Presents Interim Results for Phase 2 Carcinoid Tumor Study
5. EntreMed to Present at BIO CEO and Investor Conference
6. EntreMed Reports Fourth Quarter and Year-End 2007 Financial Results
7. EntreMed Announces 2008 Corporate and Clinical Program Priorities
8. EntreMed to Present at BioCentury Future Leaders in the Biotech Industry Conference
9. EntreMed Receives Nasdaq Deficiency Notice
10. EntreMeds Kinase Inhibitor, ENMD-2076, Presented During AACR Special Session
11. EntreMed Will Not Seek Shareholder Approval for Reverse Stock Split at Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)...  Therapath Neuropathology ( www.Therapath.com ), a leader ... and Military Medical centers both domestically and worldwide.  ... Sweat Gland Nerve Fiber Density (SGNFD) for the ... Demonstration of a reduction in ... skin biopsy is a highly sensitive and specific ...
(Date:7/29/2015)... , July 29, 2015  Indivior PLC (LON: ... for naloxone nasal spray was accepted and received Priority ... for the treatment of opioid overdose. This naloxone nasal ... specially formulated for optimal absorption into the nasal mucosa. ... minimal training so individuals may be better equipped to ...
(Date:7/29/2015)... - RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSX.V: RP), ... announce that the final design specifications of its ... for industrial and regulatory testing will now be ... mark clearance to market the injector in ... (Photo: http://photos.prnewswire.com/prnh/20150729/248373 )  The RCI-02 ...
(Date:7/29/2015)... ... July 29, 2015 , ... Finding gooey or crusty material ... normal. Although there are a considerable number of terms in popular use to describe ... material is a mixture of mucus, blood cells, skin cells and dust, but until ...
Breaking Biology Technology:Neuropathology services for VA and Military health systems 2Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 2Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 3Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 4Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 5RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 2RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 3RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 4RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 5What Are ‘Eye Crusties’ Made Of? uBiome Invites Citizen Scientists to Find Out 2What Are ‘Eye Crusties’ Made Of? uBiome Invites Citizen Scientists to Find Out 3What Are ‘Eye Crusties’ Made Of? uBiome Invites Citizen Scientists to Find Out 4
... (Nasdaq: BMRN ) today announced that Dr. Emil Kakkis, ... 2009. Dr. Kakkis has,decided to leave his position with the ... time to personal endeavors related to rare diseases. Dr.,Kakkis will ... , "I am extremely grateful ...
... Nov. 21 MichBio, the association for,Michigan,s biosciences ... to its fourth annual Expo on Tuesday and ... in Novi, MI. The MichBio Expo is,the ... addition, this year,s event attracted 56 exhibitors. The ...
... Lilly and,Company (NYSE: LLY ) and ImClone Systems ... of the previously announced tender offer,by Lilly,s wholly-owned subsidiary, Alaska ... of $70.00 per share in cash. The,offer expired at ... The depositary for the tender ...
Cached Biology Technology:BioMarin Announces the Planned Retirement of Dr. Emil Kakkis, Chief Medical Officer 2BioMarin Announces the Planned Retirement of Dr. Emil Kakkis, Chief Medical Officer 3BioMarin Announces the Planned Retirement of Dr. Emil Kakkis, Chief Medical Officer 4MichBio Expo Draws Nearly 500 Professionals; Career Day Raises Profile 2MichBio Expo Draws Nearly 500 Professionals; Career Day Raises Profile 3Lilly Completes Cash Tender Offer for ImClone Systems 2Lilly Completes Cash Tender Offer for ImClone Systems 3
(Date:7/30/2015)... July 30, 2015 Cellecta, Inc., a ... function analysis and biomarker discovery, announced the release ... Library targeting all human protein coding genes. CRISPR ... out" a gene,s function. Cellecta,s new Human Whole ... screening tool so that researchers can investigate in ...
(Date:7/27/2015)... SAN JOSE, Calif. , July 27, 2015 ... leading developer of human interface solutions, today announced ... ClearPad ® touchscreen solution for its stylish ... controller for its proven reliability, low power and ... with a wet finger. Huawei designers also required ...
(Date:7/27/2015)... 2015   Zynx Health ™, the market ... solutions, today announced that its ZynxCarebook ™ ... Android smartphones and tablets. With this expansion, care ... use ZynxCarebook to securely exchange messages and share ... transitions to other care settings, and improve clinical ...
Breaking Biology News(10 mins):CELLECTA, INC. Announces Launch of Human Whole Genome CRISPR Knockout Library 2Synaptics Touchscreen Solution Powers New Huawei Watch 2Synaptics Touchscreen Solution Powers New Huawei Watch 3Zynx Health Adds Android Device Support to ZynxCarebook Solution 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 3
... Society (ACS) News Service Weekly PressPac with news from ... credit the individual journal or the American Chemical Society ... ARTICLE #1 FOR IMMEDIATE RELEASE , Hyped-up hopes for ... reporting an advance towards tapping the immense potential of ...
... biomedical researchers from the USC Viterbi School, the College and ... $6-million Bioengineering Research Partnership grant from the National Institutes of ... older adults who suffer from significant vision loss. ... Norberto Grzywacz, professor of biomedical engineering in the Viterbi School ...
... California, Irvine scientists have discovered how to reverse the ... form of mental impairment. Neurobiologist Julie Lauterborn and ... fragile X syndrome blocks brain cells from locking new ... X mental retardation 1 (Fmr1) -- is turned off ...
Cached Biology News:American Chemical Society's Weekly PressPac -- Oct. 3, 2007 2American Chemical Society's Weekly PressPac -- Oct. 3, 2007 3American Chemical Society's Weekly PressPac -- Oct. 3, 2007 4American Chemical Society's Weekly PressPac -- Oct. 3, 2007 5American Chemical Society's Weekly PressPac -- Oct. 3, 2007 6American Chemical Society's Weekly PressPac -- Oct. 3, 2007 7American Chemical Society's Weekly PressPac -- Oct. 3, 2007 8USC biomedical team to participate in $6 million low vision project 2USC biomedical team to participate in $6 million low vision project 3USC biomedical team to participate in $6 million low vision project 4UCI researchers restore memory process in most common form of mental disability 2
... product has been developed to significantly increase ... proteins. Stability is increased at room ... centigrade. This product is subjected to ... or azide. This formulation insures consistently ...
... ThermoStat Plus accurately and conveniently controls the temperature ... maintains different temperature levels up to 99 C*, ... temperatures as low as 5 C. The thermoblocks ... ml tubes, and microplates enable a high degree ...
... developed to significantly increase the shelf life ... is increased at room temperature storage conditions ... product is subjected to 0.2 micron filtration, ... This formulation insures consistently high levels of ...
...
Biology Products: